viewNetScientific PLC

NetScientific follows its money as investee company announces plans to raise US$45mln

NetScientific currently has a 5.7% stake in PDS Biotechnology, which is at the cutting edge of immuno-oncology

NetScientific PLC -

NetScientific PLC (LON:NSCI) said it is participating in the latest funding round by investee company PDS Biotechnology Corporation (NASDAQ:PDSB).

It said it is buying shares worth US$510,000 and is funding the transaction from a loan facility.

PDS said on Tuesday it plans to raise around US$45mln via the issue of new stock.

Once the fundraiser is complete, NetScientific expects its stake in the US biotech to be diluted down slightly to 4.86% from 5.7% currently. The holding is worth around £8.3mln at current prices.

PDS is a clinical-stage life sciences group whose main platform, Versamune, trains the immune system to unleash powerful targeted T-cell attacks that could “dramatically improve treatment and patient outcomes across the cancer spectrum”.

Dr Ilian Iliev, NetScientific chief executive who sits on the board of the US-listed investee firm, said: "Following a transformational year for PDS, and growing market recognition of the potential of its Versamune platform, this latest investment provides PDS with the resources to continue executing its ambitious strategy in the immuno-oncology space."

Quick facts: NetScientific PLC


Price: 110 GBX

Market Cap: £23.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


NetScientific invest £1m in Martlet Capital 'fitting with strategy to...

NetScientific PLC (AIM:NSCI, FRA:NTK1) (AIM:NSCI, FRA:NTK1) chief executive, Dr Ilian Iliev joins Proactive after announcing their news to invest an initial £1mln in Martlet Capital, which has been set up to acquire a portfolio of minority interests in growth companies operating in the Cambridge...

4 days, 3 hours ago

2 min read